www.praktickelekarenstvi.cz e50 PRAKTICKÉ LÉKÁRENSTVÍ AKTUÁLNÍ FARMAKOTERAPIE Polékové akutní poškození ledvin Ther 2016; 167: 132–145. 10. Camin RM, et al. Acute kidney injury secondary to combination of renin-angiotensin systém inhibitors, diuretics and NSAIDs: „the triple whammy“. Nefrologia 2015; 35: 197–206. 11. Dreischulte T, et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin systém inhibitors in the community increases the risk of acute kidney injury. Kidney Int 2015; 88: 396–403. 12. Zager RA. Pathogenetic mechanisms in nephrotoxic acute renal failure. Semin Nephrol 1997; 17: 3–14. 13. Markowitz GS, et al. Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta 2005; 351: 31–47. 14. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008; 78: 743–750. 15. Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001; 60: 804–817. 16. Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin AJ Am Soc Nephrol 2017; 12: 2046–2049. 17. Douros A, et al. Drug-induced kidney injury: a large case series from the Berlin Case- -Control Surveillance Study. Clin Nephrol 2018; 89: 18–26. 18. Perazella MA. Pharmacology behind common drug nephrotixicities. Clin J Am Soc Nephrol 2018; 13: 1897–1908. 19. Shahrbaf FG, Assadi F. Drug-induced renal disorders. J Renal Inj Prev 2015; 4: 57–60. 20. Piereson-Marchandise M, et al. The drugs that mostly frequently induce acute kidney injury: a case-noncase study of a pharmacovigilance database. Br J Clin Pharmacol 2017; 83: 1341–1349. 21. Zhang X, et al. Non-steroidal anti-inflammatory drug Induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 2017; 18(1): 256. doi: 10.1186/s12882–017–0673–8 22. Gayat E, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers in post-ICU discharge outcome in patients with acute kidney injury. Intensive Care Med 2018; 44: 598–605. 23. Saly DL, Perazella MA. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Am J Physiol Renal Physiol 2017; 313: F951–F954. doi: 10.1152/ajprenal.00250.2017. 24. FDA Adverse Event Reporting System (FAERS) Public Dashboad [cit. 2020-03-23]. Dostupné z: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard. 25. Perlman A, et al. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report systém database. Nutr metqab Cardiovasc Dis 2017; 27: 1108–1113. 26. FDA Drug Safety Communitation 6–14–2016: FDA strenghtens kidney warning for diabetes Medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XE). Dostupné z: https://www.fda.gov/media/98683/download. 27. Perlman A, et al. Clinical spectrum and mechanism of acute kidney injury in patients with DM on SGLT-2 inhibitors. IMAJ 2018; 20: 513–515. 28. EMA: EPAR-Product Information Invokana (kanagliflozin), Muntipharma 2020/2. Dostupné z: https://www.ema.europa.eu/en/medicines/human/EPAR/invokana#product- -information-section 29. Kubát K, et al. 23 případů metforminem indukované metabolické laktátové acidózy. Klin Biochem Metab 2017; 15: 77–85. 30. Svoboda L. Poškození ledvin kontrastní látkou. Med. Pro Praxi 2007; 4: 410–415. 31. SPC ČR: Siofor (metformin), Berlin-Chemie, 2020/7. Dostupné z: http://www.sukl.cz/modules/medication/search.php)
RkJQdWJsaXNoZXIy NDA4Mjc=